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Thrombotic events that frequently occur in Coronavirus disease 2019 (Covid-19) are 
predominantly venous thromboemboli (VTE) and are associated with increasing 
disease severity and worse clinical outcomes. Distinctive microvascular 
abnormalities in Covid-19 include endothelial inflammation, disruption of intercellular 
junctions and microthrombi formation. A distinct Covid-19 associated coagulopathy 
along with increased cytokines and activation of platelets, endothelium and 
complement occur in Covid-19, which is more frequent with worsening disease 
severity. This pro-inflammatory milieu may result in immunothrombosis, a host 
defence mechanism that can become dysregulated, leading to excess formation of 
immunologically mediated thrombi which predominantly affect the microvasculature. 
The haemostatic and immune systems are intricately linked, and multifactorial 
processes are likely to contribute to VTE and immunothrombosis in Covid-19. This 
state of the art review will explore the pathobiological mechanisms of 
immunothrombosis and VTE in Covid-19 focusing on: Covid-19 associated 
coagulopathy, pathology, endothelial dysfunction & haemostasis, the immune 
system & thrombosis, genetic associations and additional thrombotic mechanisms. 
An understanding of the complex interplay between these processes is necessary for 
developing and assessing how new treatments affect VTE and immunothrombosis in 
Covid-19. 
 














Coronavirus disease 2019 (Covid-19) is caused by the novel severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) that has disseminated in a global 
pandemic. SARS-CoV-2 is a single-stranded RNA virus, of the genus 
betacoronavirus, that enters cells via angiotensin converting enzyme 2 (ACE2) 
receptors.1 SARS-CoV-2 has homology to SARS-CoV-1 and Middle East respiratory 
syndrome coronavirus (MERS-CoV), which caused the 2002/3 SARS and 2012 
MERS outbreaks respectively.1–3 Covid-19 pneumonia can cause fever, cough and 
dyspnoea with approximately 15% of cases being severe and 5% requiring intensive 
care support for acute respiratory distress syndrome (ARDS) or multi-organ failure.4 
Demographics and comorbidities that are associated with Covid-19 include older 
age, male sex, ethnicity, diabetes, systemic hypertension and chronic 
cardiorespiratory disease.5,6 
 
Thrombotic events occur in up to one third of Covid-19 patients, which are 
predominately pulmonary emboli, and are associated with more severe disease and 
increased mortality.7,8 However, studies are heterogenous and incidence varies by 
cohort composition (e.g. disease severity, definition of thrombotic events), 
investigations performed, and the use of thromboprophylaxis.9 Venous 
thromboembolism (VTE) incidence is high in other viral diseases including SARS-
CoV-1 and H1N1 however, a direct comparison with Covid-19 is challenging due to 
varied cohorts and methodologies.10,11 VTE rates are higher in severe Covid-19 than 
matched groups with ARDS, suggesting the high incidence is due to mechanisms in 
addition to VTE risk factors in hospitalised patients (e.g. immobility and severe 
illness).12 Furthermore, VTE may be under-recognised in Covid-19 as the incidence 
increases when screening investigations are performed however, this may also apply 
to other diseases.13 Smaller pulmonary (micro)thrombosis in Covid-19 may represent 
in-situ immunothrombosis, a process initiated by the innate immune system that 
involves cross-talk with haemostasis.8,14,15 There is current uncertainty about 
whether Covid-19 associated thrombotic events are due to conventional VTE, 
immunothrombosis or a combination, which has important implications for diagnostic 




We aim to review the pathobiological mechanisms of immunothrombosis and VTE in 
Covid-19 focusing on: Covid-19 associated coagulopathy (CAC), pathology, 
endothelial dysfunction & haemostasis, the immune system & thrombosis, genetic 
associations and additional thrombotic mechanisms. A literature search (MEDLINE) 
was performed in June 2020 using the following search terms (including variations 
and acronyms): “Covid-19”, “venous thromboembolism”, “immunothrombosis”, 
“coagulopathy”, “endothelial dysfunction”, “platelet”, “cytokine” and “complement”. 
 
 
COVID-19 ASSOCIATED COAGULOPATHY  
Covid-19 patients can have mild thrombocytopenia, mildly prolonged prothrombin 
time, increased fibrinogen and raised D-dimer (table 1), all of which are more 
pronounced as disease severity increases.16,17 This pattern of CAC shares features 
with sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation 
(DIC), but is a distinct entity.18 DIC and SIC can occur in Covid-19, but are less 
common when validated diagnostic criteria are applied.18 Similar CAC findings have 
also been reported in SARS-CoV-1 infections.10 
 
D-dimer is a fibrin degradation product that is sensitive at detecting fibrinolysis of 
intravascular thrombus (i.e. VTE) but lacks specificity and can be raised in 
inflammation and other diseases.19 A marked increase in D-dimer can occur in 
Covid-19 and has been independently associated with mortality.20,21 Raised D-dimer 
may be related to Covid-19 acute lung injury and produced by the breakdown of 
intra-alveolar fibrin, which is deposited in ARDS.22,23 
 
Additional markers of coagulation and inflammation can also be abnormal in Covid-
19 including ferritin, von Willebrand Factor (VWF), C-reactive protein (CRP), 
complement and cytokines (table 1). This suggests a complex interaction between 
the haemostatic and immune systems that may contribute to a prothrombotic 
phenotype that is discussed in this review. 
  
 
Blood test Direction of 
change 
Comparator 
(case vs. control) 
Reference(s) 
D-dimer ↑ Severe vs. non-severe 17 
Fibrinogen ↑ ICU vs. ref range 16 
Platelets → / ↓ Severe vs. non-severe 17,24 
aPTT → Severe vs. non-severe 17,25 
PT → / ↑ Severe vs. non-severe 17,26 
Antithrombin → / ↑ Covid-19 vs. healthy 
control 
27 
PAI-1 ↑ Autopsy vs. ref range 28 
Leucocytes ↑ Severe vs. non-severe 17 
Lymphocytes ↓ Severe vs. non-severe 17  
Neutrophils ↑ Severe vs. non-severe 17 
Factor VIII ↑ ICU vs. non-ICU 29 
VWF ↑ ICU vs. non-ICU 29 
Soluble P-selectin ↑ ICU vs. non-ICU 29 
CRP ↑ Severe vs. non-severe 17 
Procalcitonin ↑ Severe vs. non-severe 17,25 
Ferritin ↑ Severe vs. non-severe 25 
Complement ↑  Autopsy vs. ref range 30 
 
Table 1. Blood markers of coagulation, fibrinolysis and inflammation in Covid-
19. Arrows indicate the direction of change (↑ = increase, ↓ = decrease, → = no 
 
change) in Covid-19 with respect to a control group or reference range defined in the 
comparator column. The magnitude of change (i.e. marked increase vs. mild 
increase) is not indicated in this table. Activated partial thromboplastin time (aPTT), 
C-reactive protein (CRP), intensive care unit (ICU), plasminogen activator inhibitor 1 
(PAI-1), prothrombin time (PT), reference (ref), von Willebrand factor (VWF). 
 
 
COVID-19 PATHOLOGY  
SARS-CoV-2 has a predilection for the respiratory tract, gaining cellular entry via the 
ACE2 receptor that is expressed on the surface of airway epithelial cells.31,32 
Pathological changes in Covid-19 include diffuse alveolar damage, activation of type 
II pneumocytes, hyaline membrane formation and fibrin deposition; changes 
consistent with ARDS.33,34 Distinctive pulmonary microvascular abnormalities occur 
in Covid-19 that include intravascular fibrin deposition, perivascular monocyte 
infiltration, angiogenesis and microthrombi formation.33,34 Pulmonary endothelial cell 
inflammation, membrane disruption and damage are prominent features that may 
result from direct viral effects, consistent with endothelial ACE2 receptor expression, 
or indirect host inflammatory effects.23,35 Importantly, the microvascular changes in 
Covid-19 are more pronounced than in H1N1 infected lungs, suggesting disease 
specific effects rather than epiphenomenon of ARDS or viral pneumonia.23 VTE 
occurs in up to 50% of Covid-19 autopsy series and the frequent occurrence of DVT 
suggests embolic complications in addition to in-situ microvascular 
immunothrombosis.33,36 The ACE2 receptor is widely expressed by different cells 
and SARS-CoV-2 has been detected in the kidneys, liver, heart and brain, which 
may account for extra-pulmonary thrombotic complications along with the ubiquitous 
presence of endothelium in different organs.7,32,37 
 
Pulmonary thrombosis in Covid-19 may represent conventional PEs or 
immunothrombosis (particularly for smaller clots) however there is no current 
differentiating diagnostic strategy. The pathological changes from autopsy series 
suggest a combination of these two processes occurs in Covid-19, although this may 




ENDOTHELIAL DYSFUNCTION & HAEMOSTASIS 
The endothelium is a monocellular layer lining blood vessels with functions that 
include providing a mechanical barrier between circulating blood and the basement 
membrane, controlling vascular tone and immunomodulation.38 Endothelial 
dysfunction involves endothelial activation and reduced endothelium-dependent 
vasodilation, which results in a proinflammatory, procoagulant and proliferative 
state.39 Covid-19 clinical outcomes are worse in patients with diseases associated 
with endothelial dysfunction (e.g. systemic hypertension, diabetes and obesity) and 
evidence of endothelial dysfunction is present in Covid-19 autopsy series.23,40 The 
mechanism(s) for endothelial dysfunction could occur via direct SARS-CoV-2 
invasion of endothelial cells or indirect inflammatory effects.23,41 Binding of the 
SARS-CoV-2 spike protein to the ACE2 receptor is facilitated by host serine 
protease TMPRSS2 priming, followed by viral endocytosis and replication.31,41 
Subsequent endothelial damage and viral release triggers a marked immune 
response that could cause additional endothelial dysfunction (see: The immune 
system and thrombosis section). 
 
Haemostasis overview 
A prothrombotic state occurs in Covid-19 that could be a consequence of increased 
coagulation, decreased fibrinolysis and immune effects. Coagulation involves a 
complex biological cascade and is a component of haemostasis along with vascular 
spasm and platelet activation. Endothelial damage and disruption of intercellular 
junctions in Covid-19 exposes the subendothelial matrix containing tissue factor (TF) 
and collagen.23,42 This activates the coagulation cascade and results in thrombin 
generation and conversion of fibrinogen to fibrin which, together with platelet 
aggregates, forms blood clots (figure 1).42 Mild prolongation of prothrombin time in 
CAC (particularly in severe disease), could signify activation of the TF (extrinsic) 
pathway (figure 1). TF is a subendothelial transmembrane protein and FVII/FVIIa 
cofactor that potently activates the coagulation cascade.43,44 In Covid-19, TF 
expression on macrophages and platelets could be induced by inflammatory 
cytokines.43 Furthermore, tissue factor pathway inhibitor (TFPI), which inhibits the TF 
 
pathway, could be impaired by inflammation in Covid-19 leading to further 
coagulation.45 Endogenous anticoagulant levels (α2-antiplasmin, protein C/S, 
antithrombin) are normal in Covid-19, which is further evidence that CAC is distinct 
from DIC.29 Markers of endothelial activation (VWF, FVIII, P-selectin) are increased 
in Covid-19, and raised soluble thrombomodulin (an endothelial glycoprotein) 
together with VWF are associated with worse clinical outcomes.29 Importantly, the 
presence of endothelial activation and haemostatic abnormalities in intensive care 
unit (ICU) and non-ICU Covid-19 patients suggests these processes are important in 
disease pathophysiology and not only an epiphenomenon of ARDS (figure 2).29,46 
 
Fibrinolysis 
Reduced fibrinolysis has been described in severe Covid-19 and increased VTE 
occurs in patients with more severe abnormalities of clot dissolution.16 The 
combination of raised D-dimer (a marker of fibrinolysis) and evidence of apparent 
hypofibrinolysis has been proposed to either be a consequence of differences 
between systemic and local effects, or due to the fibrinolytic system becoming 
overwhelmed.47,48 The fibrinolytic inhibitor plasminogen activator inhibitor 1 (PAI-1) is 
increased in Covid-19, SARS-CoV-1 infection and other causes of ARDS where 
hypofibrinolysis and fibrin deposition are hallmark features.28,29 Inflammation 
promotes PAI-1 release from endothelial cells, which suppresses urokinase- (uPA) 
and tissue-type plasminogen activator (tPA) from converting plasminogen to plasmin, 
which ultimately leads to reduced fibrin degradation.28 PAI-I is increased in ICU and 
non-ICU Covid-19, suggesting a role in disease pathobiology and progression that is 
not only related to ARDS.29 
 
Platelets 
Activated endothelial cells express a number of proteins including P-selectin, a cell 
adhesion molecule that enables the recruitment of platelets and leucocytes, which 
have a pivotal role in haemostasis and thrombosis.49 Disruption of the endothelial 
layer exposes the collagen containing subendothelial matrix and also results in 
platelet activation and recruitment.50 Subsequent platelet degranulation and 
aggregation produces a platelet plug that functions as an adhesion site for 
coagulation factors.50 Activated platelets secrete a range of bioactive molecules (e.g. 
 
ADP, polyphosphates, coagulation factors) and immunological mediators (e.g. 
complement factors) that cause further platelet activation and amplification of the 
immune system via positive feedback mechanisms contributing to haemostasis.50  
 
Platelet counts are normal or mildly reduced in Covid-19, unless there is concurrent 
DIC which is uncommon.18 However, marked platelet activation occurs with rapid 
aggregation and increased platelet-leucocyte aggregates that are more pronounced 
in severe Covid-19.51,52 Markers of platelet activation (e.g. P-selectin, soluble 
CD40L) are increased Covid-19 and P-selectin can induce monocyte TF expression, 
leading to a procoagulant phenotype.29,52 The glycoprotein VWF produced by 
activated endothelial cells, platelets or exposed subendothelium mediates platelet 
adhesion and aggregation.53 VWF is markedly increased in Covid-19, which could 
signify a propensity for platelet plug formation and thrombosis.29 Platelets have an 
important function in the innate immune system and activated platelets release 
complement (C3) which may contribute to Covid-19 immunothrombosis (see: The 
immune system and thrombosis section).54 
 
Hypoxia 
Hypoxia occurs in moderate-severe Covid-19 and this can lead to endothelial 
dysfunction and hypercoagulability.55,56 Upregulation of endothelial P-selectin and 
adhesion molecules (e.g. intercellular adhesion molecule-1 (ICAM-1)) in hypoxia 
results in platelet and leucocyte recruitment.57 Monocytes bind to activated 
endothelial cells through the P-selectin glycoprotein ligand-1, and further express 
prothrombotic factors such as TF.58  
 
Hypoxia-induced factors (HIFs) are transcription factors expressed by endothelial 
and immune cells in response to hypoxaemia.59 HIFs promote thrombosis by 
increasing endothelial release of PAI-1 and inflammatory cytokines (e.g. Tumour 
necrosis factor (TNF), Interleukin(IL)-2), while downregulating thrombomodulin.56,57 
Additionally, HIF activity can initiate the immune system; a hypoxic environment can 
cause release of damage-associated molecular patterns (DAMPs), that potently 
trigger an immune response (see: The immune system and thrombosis section). 
In macrophages, HIFs promote their activation and local aggregation, along with 
driving the expression of pro-inflammatory cytokines including IL-6 and TNF-ɑ.59 HIF-
 
1α could enhance complement-mediated endothelial damage in Covid-19 by 
decreasing the expression of the complement regulator CD55.60 The cumulative 
effects of hypoxia are a likely contributor to dysregulated haemostasis and disruption 
of vascular tone in Covid-19. 
 
Vasoconstriction 
Loss of vascular tone is a feature of endothelial dysfunction and, when culminating in 
vasoconstriction, can have prothrombotic consequences. A number of hypoxia-
dependent pathways can drive this process. Hypoxia-induced expression of 
adhesion molecules, namely P-selectin, E-selectin, ICAM-1 and vascular cell 
adhesion molecule-1 (VCAM-1) disrupts the endothelium. Subsequent increase in 
microvascular permeability exposes the subendothelial matrix, rapidly triggering 
thrombosis.57 Alveolar and tissue hypoxia in severe Covid-19 may initiate the 
cyclooxygenase (COX) pathway in endothelial cells; binding of COX-induced 
thromboxanes A2 and B2 to thromboxane prostanoid receptors initiates constriction 
of vascular smooth muscle cells.57  
Vascular tone is also regulated by hypoxia-independent mechanisms, including the 
renin-angiotensin-aldosterone system. ACE2 cleaves angiotensin II (AngII) to 
angiotensin 1-7 (Ang1-7) and downregulation of the ACE2 receptor, following 
internalisation with SARS-CoV-2, would suppress Ang1-7-mediated vasodilation 
(figure 2).61 The subsequent accumulation of AngII, and binding to angiotensin II 
receptor type 1 (AT1), could augment pulmonary vasoconstriction and promote 
induction of TF and PAI-1 expression on platelets and the endothelium.43,61,62 
Increased AngII occurs in Covid-19 and has been associated with viral load and lung 
injury.63 Imbalance of ACE2/AngII may in part explain the association of pre-existing 
vascular diseases (e.g. systemic hypertension, diabetes) with susceptibility to severe 
Covid-19 as these diseases have altered baseline levels of ACE2.63 
 
THE IMMUNE SYSTEM AND THROMBOSIS 
Haemostasis and the immune system are intricately related, with the two systems 
complementing each other to provide host defence and limit the dissemination of 
invading pathogens. Physiological immunothrombosis can become dysregulated 
 
resulting in excessive formation of immunologically-mediated thrombi that 
predominantly affect the microvasculature.15 Immunothrombosis has been proposed 
as an important pathological mechanism in Covid-19 patients, whereby innate 
immune cell activation, excessive coagulation and endothelial dysfunction contribute 
to the observed prothrombotic state.64 Interaction between the haemostatic and 
innate immune systems, particularly monocytes, macrophages and neutrophils, is 
the cardinal feature of immunothrombosis (figure 3). Activation of innate immunity 
can be induced by the coagulation system; thrombin and factor Xa can activate 
innate immune cells through their protease-activated receptors (PARs). Similarly, 
fibrinogen and fibrin have been shown to initiate the activation of neutrophils.15 
In Covid-19, vascular injury is induced by endocytosis of SARS-CoV-2 by host cells, 
causing them to undergo pyroptosis.41 Pyroptosis is an extremely inflammatory form 
of programmed cell death that terminates in cell lysis, causing the release of various 
DAMPs including ATP, nucleic acids and inflammasomes. Pyroptosis also releases 
non-encapsulated viral RNA and proteins that can infect surrounding host cells and 
further amplify the inflammatory milieu. DAMPs bind pattern recognition receptors 
(PRRs), present on the surface of local epithelial cells, endothelial cells and 
monocytes.41 Ligation of viral ssRNA and dsRNA (which serve as pathogen-
associated molecular patterns (PAMPs)) with PRRs and toll-like receptors (TLRs), 
on the surface of macrophages, triggers their activation and further exacerbates the 
proinflammatory response. Recognition of PAMPs through the TLR and CD14 
receptor of monocytes promotes the transcription and expression of TF.15,65 The 
cumulative response of the immune system to SARS-CoV-2, both through 
inflammation and immune cell expression of prothrombotic proteins, is likely to be a 
major contributor to hypercoagulability in Covid-19. 
Cytokines and chemokines  
Severe Covid-19 is characterised by the increased activation of the innate immune 
system and increased inflammation.41 This is associated with an amplified and 
uncontrolled release of cytokines, a phenomenon that has been termed cytokine 
storm.66 Cytokines and chemokines are proteins secreted by a host of immune cells, 
and serve as an important innate defence mechanism. They recruit adaptive immune 
cells, and regulate a wide range of processes in the immune system.67 In Covid-19, 
 
numerous cytokines and chemokines are increased; IL-6, interferon (IFN)-γ, and IL-2 
are among the most commonly reported elevated cytokines.66,68 IL-6 increases 
platelet production and activity, increases the expression of TF on endothelial cells 
and monocytes, and can also give rise to endothelial dysfunction.66,68 IFN-γ similarly 
increases platelet production and impairs the vascular endothelium, giving rise to 
prothrombotic effects.68 IL-2 can decrease fibrinolysis by up-regulating PAI-1.68 IL-8 
is also elevated in Covid-19, and can attract neutrophils to the site of infection, which 
predisposes to the formation of neutrophil extracellular traps (NETs).66 Whilst 
cytokines have prothrombotic effects, the degree that this applies to Covid-19 
immunothrombosis requires further investigation and reverse causation 




Complement activation is observed in Covid-19, with the deposition of the terminal 
complement complex C5b-9 and MASP2 protein in lung lesions.30 Complements are 
proteins that enhance the function of phagocytic cells and facilitate antibody 
opsonisation, serving as an important host defence mechanism of the innate immune 
system. They are produced as dormant factors by the liver, and in Covid-19 they are 
activated by the alternative and lectin pathways.30 The complement system involves 
a cascade of processes, culminating in the formation of the terminal C5b-9 
membrane attack complex (MAC), which is observed in Covid-19.30 The insertion of 
a MAC into the cell membrane of infected cells or directly onto pathogens creates a 
transmembrane channel, triggering cell lysis and death.69 MACs can also activate 
platelets, induce endothelial secretion of VWF, and cause endothelial damage when 
inserted into endothelial cells.69 When these normal defences against pathogens are 
hyperactivated, they result in excess endothelial damage that can serve as foci for 
thrombosis. The individual complement components are prothrombotic, for example, 
C5a can upregulate the activity of TF and PAI-1 and can also activate neutrophils, 
resulting in increased IL-6 and IL-8 production, while also promoting the formation of 
NETs.69 The serine protease MASP2 is increased in Covid-19 and may promote clot 
formation by activating C2 and C4, which increase the activity of thrombin, fibrinogen 
and factor XIII.30,70 Complement activation is likely to augment the Covid-19 
 
prothrombotic phenotype and future research should clarify the specific components 
of the complement system involved and the effect of modulation.  
 
Neutrophil extracellular traps 
Neutrophils are important contributors to the formation of thromboses and rapidly 
migrate to the site of endothelial damage alongside platelets.71 An important defence 
mechanism, known as NETosis, is deployed by activated neutrophils to clear 
pathogens and could be relevant to thrombosis in Covid-19 (figure 3).72 NETosis 
involves the extracellular release of NETs, which are composed of chromatin and 
microbicidal proteins.73 NETs have been implicated in the pathobiology of thrombosis 
in VTE, as well as ARDS and sepsis, with serum levels of NETs correlating with 
mortality.74,75 
 
NET-driven thrombosis is largely platelet-dependent; neutrophils recognise and bind 
P-selectin, expressed by activated platelets, through their PSGL-1 receptor which 
triggers NETosis.71 NETs can also interact with VWF, released by endothelial cells 
and platelets, which leads to platelet adhesion and fibrin formation.76,77 Histone 
proteins in the DNA fragments of NETs, serve as potent DAMPs which can further 
attract platelets and thereby initiate a positive feedback loop.71 Release of neutrophil 
elastase, a serine protease, during NETosis has previously been shown to inhibit 
anticoagulation by degrading TFPI and thrombomodulin.78 Degradation of these 
endogenous anticoagulants permits the unprohibited action of TF.79 Serine 
proteases also degrade alveolar surfactant cells which are important in the clearance 
of inflammatory cells.75 
 
The detrimental effects of NETs have previously been described in sepsis and 
ARDS, whereby NETs have been shown to induce damage to host tissue at the site 
of injury, thus exacerbating local inflammation and propagating microvascular 
thrombosis. Case reports in severe Covid-19 have described evidence of NETs, with 
sera derived from hospitalised patients containing markers of NETs, including 
elevated levels of citrullinated histone H3 and myeloperoxidase-DNA.72 A study 
utilising autopsy-derived tissue from Covid-19 patients reported neutrophil activation 
and the presence of NET aggregates within the microvasculature, resulting in 
vascular occlusion and consequent organ damage.80 NET formation may be 
 
augmented by the described pro-inflammatory and procoagulant factors in Covid-19, 
contributing to a thrombotic phenotype.  
COVID-19 AND VTE GENETIC ASSOCIATIONS 
VTE is a polygenic disease associated with common and rare genetic variants 
including heritable thrombophilias (e.g. Factor V Leiden, prothrombin mutations and 
antithrombin, protein C/S deficiencies). A genome-wide association study (GWAS) of 
patients with severe Covid-19 identified genetic associations in the ABO gene and in 
a chromosome 3 locus (3p21.31) spanning several genes (SLC6A20, LZTFL1, 
CCR9, FYCO1, CXCR6 and XCR1).81 When ABO blood groups were inferred in this 
GWAS, the A group was enriched in the severe Covid-19 patients whilst the O group 
was underrepresented. ABO is a pleiotropic locus that is associated with thrombotic 
diseases including VTE.82 The differential thrombotic risk of ABO blood groups has 
traditionally been attributed to VWF levels, which are 25% lower in O group 
individual.83 ABO is also associated with IL-6 levels which, together with VWF, are 
increased in Covid-19.84 Alternatively, anti-A antibodies in blood group O and B 
individuals may inhibit the SARS-CoV-2 virus and ACE2 receptor interaction.85,86 
Multiple plasma protein levels are associated with ABO, relating to immunology, 
endothelial cell function and coagulation.87 Alternative functional consequences of 
ABO genetic variation include influencing DC-SIGN levels, a membrane receptor 
expressed by dendritic cells and a proposed binding site for SARS-CoV-2.88,89  
 
The candidate gene SLC6A20 in the 3p21.31 GWAS locus encodes the SIT1 
transporter protein that functionally interacts with the ACE2 receptor, and the 
3p21.31 locus is putatively associated with levels of the chemokine CXCL16; 
however, the functional consequences of the 3p21.31 genetic association require 
further investigation.81,88,89 Genetic variation in ACE2 and TMPRSS2 may influence 
Covid-19 susceptibility but this requires validation in a Covid-19 specific population.90 
Genetic variation in human leucocyte antigens could affect immune response by 
varying the affinity for SARS-CoV-2 binding.91 Furthermore, rare variants in genes 
related to type I interferon immunity are enriched in severe Covid-19.92 Ongoing 
research from global consortia aims to clarify the role of genomic variation in Covid-





ADDITIONAL THROMBOTIC MECHANISMS 
Additional mechanisms have been putatively associated with thrombosis in Covid-
19. Increased levels of ferritin in Covid-19 are likely to reflect cellular damage and 
could contribute to inflammation.25,94 High levels of ferritin may have detrimental 
effects on mitochondria, leading to the release of reactive oxygen species, which 
cause cell death.94 Mitochondrial dysfunction in platelets may contribute to 
inflammation and a prothrombotic state.94 
 
Elevated antiphospholipid antibody (APA) titres have been described in Covid-19, 
although their significance is unclear.95 APAs can interact with the endothelium, 
leucocytes and platelets, triggering the release of prothrombotic factors, and can 
also interact with the complement system.96 APAs can be raised in acute infection, 
and a diagnosis of antiphospholipid syndrome requires APAs to be measured on two 
separate occasions 12 weeks apart, which needs confirmation before being 
implicated in Covid-19 pathophysiology.95,96  
 
Obesity is a is a long-term and subacute inflammatory condition that is a risk factor 
for Covid-19 and VTE.43,97,98 Hypertrophy of adipocytes and the associated 
dysfunction in adipose metabolism causes the release of IL-6, PAI-1 and TF, which 
activate the coagulation system.98 Platelet aggregation is also promoted with the 
decreased release of adiponectin and increased release of leptin.98 Insulin 
resistance, associated with obesity, also reduces the modulatory effect that insulin 
appears to have on platelet activity.98 The inflammatory state in obesity may account 




The mechanisms contributing to increased thrombosis in Covid-19 involve extensive 
cross-talk between haemostasis and the immune system. Treatments that target 
these pathways may mitigate the adverse macro- and microvascular effects of 
Covid-19 and include anticoagulants, antiplatelets, fibrinolytics and immune 
 
modulators, with numerous studies ongoing.99 Guidelines recommend prophylactic 
anticoagulation in hospitalised Covid-19 patients and treatment dose anticoagulation 
in established VTE, with evidence indicating better clinical outcomes for 
anticoagulated patients.20,100 Ongoing studies are assessing different anticoagulation 
strategies for Covid-19. Anticoagulation may reduce propagation or additional 
formation of thrombus, but alternative strategies may be required to prevent or target 
dysregulated immunothrombosis. Additionally, cellular heparan sulfate is a proposed 
co-receptor for SARS-CoV-2 binding to ACE2, and therefore exogenous heparin 
may have effects on viral adhesion.101 Dexamethasone has a range of anti-
inflammatory and immunosuppressive effects including attenuating the function of 
immune cells, particularly T cells by suppressing their activation and proliferation. 
Dexamethasone improves clinical outcomes in hospitalised Covid-19 patients, but its 
role in controlling Covid-19 immunothrombosis is unclear.102,103 Fibrinolytics (e.g. 
recombinant tPA) have been trialled in a case-series of Covid-19 ARDS, and tPA 
may have additional anti-inflammatory effects that could be beneficial for Covid-19 
immunothrombosis.28 Anti-cytokine treatments, such as tocilizumab (directed against 
the IL-6 receptor), and anti-complement agents, such as eculizumab (directed 
against C5), are also being investigated in Covid-19 patients.66 Attenuating pro-
inflammatory pathways is likely to have downstream effects on immunothrombosis. 
However, care is required to strike the correct balance between appropriately 
targeting aberrant and dysregulated immunothrombosis, whilst not impairing its 
important physiological host defence function. 
 
Whilst research into Covid-19 associated VTE and immunothrombosis has been 
proliferating, there remain a number of knowledge gaps. Some putative 
pathobiological mechanisms have been inferred from other disease processes 
including alternative betacoronaviruses, viral pneumonias and ARDS. Dissecting and 
delineating the specific effects that SARS-CoV-2 has on thrombosis remains an 
active area of research and is crucial for guiding interventions. Areas for future 
Covid-19 research include i) whether small pulmonary thromboses represent VTE, 
immunothrombosis or a combination ii) can diagnostic strategies (e.g. radiological, 
biochemical) accurately diagnose and differentiate between VTE and 
immunothrombosis iii) can the risk of immunothrombosis be accurately predicted  iv)  
can immunothrombosis be prevented with prophylactic anticoagulation, or treated 
 
with anticoagulation v) developing novel immunothrombosis targeted interventions 
and defining how other Covid-19 treatments (e.g. dexamethasone) affect 
immunothrombosis / VTE in Covid-19.  
 
Most Covid-19 studies have been cross-sectional in patients with more severe 
disease. To fully understand the immuno-haemostatic cross-talk leading to 
immunothrombosis, longitudinal measurements in different cohorts would be 
required, which would guide the optimal timing and cohorts where intervention would 
be beneficial. An increasing understanding of the complex pathobiological interplay 
between the immune system and haemostasis in Covid-19 will help in developing 






Figure 1. Clotting cascade abnormalities in Covid-19.  
The coagulation cascade is initiated by exposure to prothrombotic proteins from the 
subendothelium or following expression of tissue factor, referred to as the intrinsic 
pathway and extrinsic pathways, respectively. Clinical investigation of the intrinsic 
and extrinsic pathways can be measured by activated partial thromboplastin time 
(aPTT) and prothrombin time (PT), respectively. A series of sequential cleavages 
occur, whereby proteolytic coagulation factors convert circulating, inactive factors 
into their active form. Both pathways reach a common pathway, by which activated 
Factor X cleaves prothrombin to form thrombin. Thrombin cleaves fibrinogen to give 
rise to fibrin strands, which rapidly polymerise to stabilise platelet aggregates and 
form a thrombus. Fibrin can be degraded by plasmin; tissue plasminogen activator 
(tPA) facilitates the cleavage of plasminogen to give rise to plasmin. Components of 
the clotting cascade that are abnormal or putatively associated with Covid-19, 
particularly severe disease, are shown in shaded symbols. In Covid-19, tissue factor 
pathway inhibitor (TFPI), Factor VIII, fibrinogen, plasminogen-activator inhibitor-1 
 
(PAI-1) and fibrin degradation products (FDPs) have been shown to be elevated. A 
prolonged prothrombin time (PT) has also been reported. Studies have shown 
reduced platelet numbers and levels of tissue plasminogen activator (tPA) in Covid-





Figure 2. Endothelial dysfunction in Covid-19  
Endothelial dysfunction in Covid-19 may occur through multiple mechanisms and 
precipitating factors. Direct invasion of SARS-CoV-2 into endothelial cells causes 
cellular damage that disturbs intercellular junctions and exposes prothrombotic 
subendothelial collagen. Internalisation of the ACE2 receptor causes an imbalance 
of Ang1-7 and AngII, in favour of the latter. Accumulation of AngII promotes the 
endothelial expression of P-selectin, TF and VWF. Intracellular viral replication within 
endothelial cells results in their activation and expression of an array of 
prothrombotic proteins. Expression of these prothrombotic proteins activates the 
extrinsic coagulation cascade. Simultaneous recruitment of platelets to the site of 
endothelial injury further contributes to hypercoagulability. Polyphosphates are 
secreted by activated platelets and promote the activation of coagulation factors. 
Polyphosphates inhibit tissue factor pathway inhibitor (TFPI) and encourage fibrin 
polymerisation. Local hypoxia exacerbates the prothrombotic phenotype, through 
induction of P-selectin, TF and VWF expression on the endothelial surface. Hypoxia-
induced activation of the COX pathway releases thromboxanes A2 and B2 (TxA2 and 
TxB2, respectively). TxA2 and TxB2 bind to thromboxane prostanoid receptors 




Figure 3. Immunothrombosis in Covid-19.  
Initial binding of SARS-CoV-2 to type II pneumocytes within the alveoli results in 
mass innate immune cell infiltration (including monocytes, macrophages and 
neutrophils). Subsequent cytokine release, from these immune cells, contributes to a 
hypercoagulable state through various proposed mechanisms. (A) Proinflammatory 
 
cytokine release can induce the release of platelets and their activation and 
aggregation. IL-6, in particular, has been shown to promote the production of 
platelets with notably more thrombogenic capacity than those produced under a non-
inflammatory environment. Cathepsin G, a serine protease produced by neutrophils, 
also activates platelets. TNF-ɑ and IL-6 upregulate TF expression by a number of 
different cell types, namely monocytes, macrophages and endothelial cells. 
Furthermore, TNF-ɑ triggers a rise in PAI-1, which in turn inhibits tPA. A consequent 
reduction in the activity of plasmin reduces fibrinolysis. (B) Complement activation is 
an important inducer of coagulation. Membrane attack complexes (MACs), also 
referred to as terminal complement complexes C5b-9, are the endpoint of a complex 
cascade of sequential cleavage and activation of complement proteins. MACs are 
constructed from a number of complement protein subunits and serve as a 
transmembrane channel, initiating cell lysis of the target cell of which they are 
embedded. Cell lysis and death of host cells contributes to coagulopathy by initiating 
microthrombi and VWF formation, as well as increasing prothrombin activity. Another 
mechanism, by which complement activation contributes to coagulation, is via 
binding of C3b to CR1 receptor, present on the membrane of platelets. Binding of 
C3b triggers the release of short-chain polyphosphate (polyP) from platelets, which 
induces the expression of TF. Complement component C5a may also contribute to 
the recruitment of neutrophils. (C) The generation of neutrophil extracellular traps 
(NETs), as a defence mechanism by neutrophils, also promotes coagulation. 
Histones, a major component of NETs, attract and bind platelets resulting in their 
aggregation. Activation of platelets, as a result of their binding to histones, induces 
TF expression. Neutrophil elastase (NE) cleaves tissue factor pathway inhibitor 
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